

RECEIVED Go to  
 SECRETARY OF THE SENATE  
 PUBLIC AFFAIRS

05 AUG 24 AM 11:18

Clerk of the House of Representatives  
 Legislative Resource Center  
 B-106 Cannon Building  
 Washington, DC 20515

Secretary of the Senate  
 Office of Public Records  
 232 Hart Building  
 Washington, DC 20510

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name			
Prefix	Mr.	First	James
		Last	Keese
2. Address <input type="checkbox"/> Check if different than previously reported			
400 North Capitol Street, NW		Suite 585	
City	Washington	State	DC
		Zip Code	20001
		Country	US
3. Principal place of business (if different than line 2)			
City		State	
		Zip Code	
		Country	
4a. Contact Name		b. Telephone number	c. E-mail
Prefix	Full Name		
Mr.	James P. Keese, III	202-737-1010	jpkeese@cagdc.com
7. Client Name <input type="checkbox"/> Self		5. Senate ID #	
Teva Pharmaceuticals USA		74556-1	
		6. House ID #	
		3604200	

**TYPE OF REPORT** 8. Year 2005 Midyear (January 1-June 30) ☒ OR Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇒ Termination Date \_\_\_\_\_ 11. No Lobbying Acti

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>80,000</u></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions or</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>
---	--

Form Co

Printed Name and Title James P. Keese, III, Principal

*James P. Keese, III*



Client Name **Teva Pharmaceuticals USA**

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code PHA - Pharmacy (one per page)

## 16. Specific lobbying issues

*Add page to continue specific issues description for this issue*

S. 975 Project Bioshield II Act of 2005, All Provisions  
S.3 Protecting America in the War on Terror Act of 2005, All Provisions

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. House or Representatives, U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue area.*

[illegible]

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Teva Pharmaceutical Industries, LTD, as an indirect parent of Teva Pharmaceuticals, USA has an interest in the listed above.

Printed Name and Title James P. Keese, III, Principal

LD-2DS (REV. 4/03)

*W. M. S.*



U

Page 4

Client Name **Teva Pharmaceuticals USA**

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code TRD - Trade (Domestic & Foreign) (one per page)

## 16. Specific lobbying issues

*Add page to continue specific issues description for this issue*

**U.S. Trade Representative Special 301 Report regarding Israeli pharmaceutical intellectual property law and generic drugs.**

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

**U.S. House of Representatives, U.S. Senate**

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue area.*

[illegible]

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Teva Pharmaceutical Industries, LTD, as an indirect parent of Teva Pharmaceuticals, USA has an interest in the listed above.

Printed Name and Title James P. Keese, III, Principal

LD-2DS (REV. 4/03)

And a page for a differen



7

Registrant Name James KeeseClient Name Teva Pharmaceuticals USA**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address

City

State

Zip Code

Country

21. Client new principal place of business (if different than line 20)

City

State

Zip Code

Country

22. New general description of client's business or activities

**LOBBYIST UPDATE**23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client:

First Name

Last Name

Suffix

First Name

Last Name

St

1

3

2

4

**ISSUE UPDATE**24. General lobbying issues that **no longer** pertain

Find the code to select below.

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal place of Business (city and state or country)
	Address	City
	C/S/Z	State
	Address	City
	C/S/Z	State
		Country

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

1

2

3

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Street Address City	Address State/Province Country	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Owr perc clien
			City		
			State		
			Country		

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, or affiliated organization

1

3

5

2

4

6

Add a page for more u

Printed Name and Title James P. Keese, III, Principal

LD-2DS (REV. 4/03)

0000443245

